BioMarin to Host 2024 Investor Day on September 4th in New York
BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) has announced its upcoming Investor Day scheduled for September 4, 2024, in New York City.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) has announced its upcoming Investor Day scheduled for September 4, 2024, in New York City. The event, running from 10:30 am to 1:00 pm Eastern Time, will be accessible via live webcast. Key highlights include:
- Presentations from executive management team
- Focus on BioMarin's pipeline and strategic plans
- Insights into growth opportunities
- Discussion of long-term financial outlook
Investors and analysts can access the webcast and presentation materials through the company's investor relations website. A replay will be available shortly after the event concludes, providing an opportunity for those unable to attend live to catch up on the important updates shared during the Investor Day.
Details
News Market Reaction – BMRN
The recorded move for BMRN in the trading session of this news was +3.61%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
-Event to be webcast live and a replay will be available
BioMarin will host a live webcast on Wednesday, September 4, 2024, at approximately 10:30 am Eastern Daylight Time. Presentation materials will also be available at investors.biomarin.com. A replay of the webcast will be available online shortly after the live webcast is completed.
About BioMarin
Founded in 1997, BioMarin is a global biotechnology Company dedicated to transforming lives through genetic discovery. The Company develops and commercializes targeted therapies that address the root cause of genetic conditions. BioMarin's unparalleled research and development capabilities have resulted in eight transformational commercial therapies for patients with rare genetic disorders. The Company's distinctive approach to drug discovery has produced a diverse pipeline of commercial, clinical, and pre-clinical candidates that address a significant unmet medical need, have well-understood biology, and provide an opportunity to be first-to-market or offer a substantial benefit over existing treatment options. For additional information, please visit www.biomarin.com.
Contacts: | |
Investors | Media |
Traci McCarty | Marni Kottle |
BioMarin Pharmaceutical Inc. | BioMarin Pharmaceutical Inc. |
(415) 455-7558 | (650) 374-2803 |
View original content to download multimedia:https://www.prnewswire.com/news-releases/biomarin-to-host-2024-investor-day-on-september-4th-in-new-york-302224592.html
SOURCE BioMarin Pharmaceutical Inc.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.